PA-3M-SoSi-H6 (Anthrax Protective Mutant Antigen (PA-3M-SoSi-H6))

Contains substitutions at three residues (D683A, L685E, Y688K) which are involved in the interaction of the protective antigen (PA) with its receptors. This mutated PA is unable to bind to its receptor. A sequence has been appended at the C-terminus which allows conjugation of diverse materials through the action of the enzyme “sortase” to redirect PA to other receptors. The C-terminal sequence added is GSGSGSLPETGGHHHHHH.

Anthrax toxin is a three-protein exotoxin secreted by virulent strains of the bacterium, Bacillus anthracis, the causative agent of anthrax. Anthrax toxin is composed of a cell-binding protein, known as protective antigen (PA), and two enzyme components, called edema factor (EF) and lethal factor (LF). Anthrax is caused by B. anthracis, a spore-forming, Gram positive, rod-shaped bacterium. The lethality of the disease is caused by the bacterium's two principal virulence factors: the polyglutamic acid capsule, which is anti-phagocytic, and the tripartite protein toxin, called anthrax toxin.

From the laboratory of Stephen H. Leppla, PhD, National Institute of Allergy and Infectious Diseases/NIH.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
PA-3M-SoSi-H6 (Anthrax Protective Mutant Antigen (PA-3M-SoSi-H6))
100ug (8.08mg/mL) In stock
Regular Price:$336.00
On Sale:

In order to purchase this product, we require a Letter of Assurance form to be completed. Download form here: PDF Kerafast Letter of Assurance


Product Type: Protein
Name: D683A, L685E, Y688K; C-terminal sequence added: GSGSGSLPETGGHHHHHH
Alternative Name(s): PA-3M-SoSi-H6
Accession ID: P13423
Strain: Expressed in avirulent engineered B. anthracisstrain BH480
Format: Purified protein (liquid)
Purity: Hydroxyapatite Chromatography
Buffer: 5 mM Hepes pH 7.5, 0.50 mM EDTA
Concentration: 8.08
Storage: -80C
Shipped: Dry ice

From the laboratory of Stephen H. Leppla, PhD, National Institute of Allergy and Infectious Diseases/NIH.
  1. Leppla SH. Production and purification of anthrax toxin. Methods Enzymol. 1988;165:103-16.
  2. Mechaly, A., McCluskey, A. J., and Collier, R. J. (2012) Changing the receptor specificity of anthrax toxin. MBio 3, e00088-00012
  3. McCluskey, A. J., and Collier, R. J. (2013) Receptor-directed chimeric toxins created by sortase-mediated protein fusion. Mol.Cancer Ther. 12, 2273-2281

If you publish research with this product, please let us know so we can cite your paper.